Behavioral effects of neonatal treatment with clomipramine, scopolamine, and idazoxan in male rats.
It has been suggested that REM sleep deprivation due to the administration of clomipramine, during early developmental stages, results in dramatic behavioral changes during adulthood. One of the main alterations is the impairment of masculine sexual behavior (MSB). Clomipramine increase monoaminergic availability at the synaptic level and also suppresses REM sleep. This study was performed to compare the effect on masculine sexual behavior of three different neonatal treatments: clomipramine, which increases monoaminergic availability at the synaptic level and suppresses REM sleep; scopolamine, a cholinergic antagonist that suppresses REM sleep; and idaxozan, a selective adrenergic agonist. Subjects (Ss) were treated neonatally and tested for masculine sexual behavior during adulthood with standard techniques. Results obtained with clomipramine administration showed a marked impairment of MSB, mainly reflected by the decrease in the percentage of active Ss and the decrease in the percentage of Ss reaching ejaculation. In contrast, idaxozan and scopolamine produce a facilitation of MSB. The effect of idaxozan was not significantly different when compared to saline control rats. The effect of scopolamine was greater, and the percentage of Ss reaching ejaculation was significantly larger than saline control. These results suggest that the alterations of sexual behavior induced with neonatally administered clomipramine are not due to early REM sleep deprivation. As idaxozan did not replicate clomipramine results, it is also possible that noradrenergic transmission is not involved in the generation of these effects. It remains possible that the serotonin system could be responsible for the impairment of sexual behavior due to neonatal clomipramine treatment.
Velazquez-Moctezuma
J
J
Departamento de Biologia de la Reproduccion, Universidad Autonoma Metropolitana-Iztapalapa, Mexico City, Mexico.
Aguilar-Garcia
A
A
Diaz-Ruiz
O
O
D058669:Adrenergic alpha-2 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn / Q000523:psychology*; D001522:Behavior, Animal / Q000187:drug effects*; D002997:Clomipramine / Q000494:pharmacology*; D004146:Dioxanes / Q000494:pharmacology*; D005260:Female; D019329:Idazoxan; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012601:Scopolamine / Q000494:pharmacology*; D012726:Sexual Behavior, Animal / Q000187:drug effects; D012895:Sleep, REM / Q000187:drug effects
D058669:Adrenergic alpha-2 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D004146:Dioxanes; D012601:Scopolamine; D002997:Clomipramine; D019329:Idazoxan